Market Update (NYSE:CAH): Bayer Appoints Cardinal Health as U.S. Based Contract Manufacturer for Xofigo® (radium Ra 223 dichloride) Injection

[PR Newswire] – WHIPPANY, N.J. and DUBLIN, Ohio, Dec. 18, 2014 /PRNewswire/ — Bayer HealthCare and Cardinal Health today announced the signing of a 15-year agreement for the contract manufacturing of Xofigo® (radium . . . → Read More: Market Update (NYSE:CAH): Bayer Appoints Cardinal Health as U.S. Based Contract Manufacturer for Xofigo® (radium Ra 223 dichloride) Injection Similar Articles: Stock Update (NYSE:CAH): Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices Company Update (NYSE:CAH): Cardinal Health Launches Online Tool To Help Retail Pharmacies Make It Easier For Patients To Compare Medicare Part D Plans Market Update (NYSE:CAH): Cardinal Health Reports Fiscal 2015 First-Quarter Results